Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.

International journal of molecular sciences - 20 Feb 2026

Zając Agnieszka E, Rutkowski Piotr, Szumera-Ciećkiewicz Anna, Piątkowski Jakub, Teterycz Paweł, Palmerini Emanuela, Dutour Aurélie, Tuziak-Klym Justyna, Wągrodzki Michał, Pieńkowski Andrzej, Tysarowski Andrzej, Gambarotti Marco, Frega Giorgio, Pierini Michela, Righi Alberto, Magagnoli Giovanna, Jean-Denis Myriam, Ibrahim Toni, Blay Jean-Yves, Golik Paweł, Czarnecka Anna M

Abstract excerpt

Chondrosarcoma (ChS) is a rare bone malignancy with heterogeneous behavior, the molecular and immunological background of which remains unknown. No effective systemic treatment for advanced ChS patients is available. The aim of this study was to develop an immune-mutational classification of ChS and to search for novel prognostic factors and molecular targets. We performed an immunological-molecular profiling of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Bone Neoplasms

Share to Chondrosarcoma

Share to IDH1 gene

Share to TP53 gene

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41752158
DOI: 10.3390/ijms27042018
PMCID: PMC12940788

Genes

IDH1
IMP3
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.PMID 41752158Read ↗

Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to ImmunophenotypeSemantic proximity Read ↗

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic TargetsSemantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.Semantic proximity Read ↗

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read ↗

The immune subtypes and landscape of sarcomasSemantic proximity Read ↗

IDH1/2 Mutations Predict Shorter Survival in ChondrosarcomaSemantic proximity Read ↗

Development And Validation of A Novel Hypoxia- And Immune-Related Prognostic Signature For Bone And Soft Tissue Sarcoma PatientsSemantic proximity Read ↗

Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision MedicineSemantic proximity Read ↗

Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity Read ↗

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade ChondrosarcomaSemantic proximity Read ↗

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.